FEATURED EDITORIAL
If the goal is more healthy years of life, the bottlenecks are target identification, target validation, and clinical testing. Why is AI not transforming those steps? Because the data are not there.
- Fragment-Based Drug Discovery 2.0, Part 1: Faster, Cleaner Weak-Binding Hit Discovery
- From Path Dependency To Demonstrable Progress: FDA Modernization Act 3.0
- How AI-Powered Automation Is Redefining Pharmaceutical R&D
- Rethinking The Blueprint For Bone Regeneration: The Next Evolution In Orthobiologics
- Pharmacogenomics In Oncology: A Pharmacokinetic Perspective
- From Valency To Vaccine Design: The Changing Competitive Landscape In Pneumococcal Vaccines
- Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)
FEATURED APPLICATION CONTENT
-
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.
-
Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.
-
See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
-
Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
-
Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.
-
High-throughput chemistry delivers speed and efficiency, but only with the right digital backbone. See how integrated automation and analytics help chemists extract more value from every plate.
- Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit
- Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)
- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 of 3)
- 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Ono Pharmaceutical Partners With Phylo To Embed Agentic AI With Every Discovery Scientist
- Bio-Thera Solutions Announces First Patient Dosed In Phase 1 Study For BAT8013, An Antibody Drug Conjugate Targeting CD25 For The Treatment Of Advanced Solid Tumors
- SITC Announces EU Immuno-Oncology Drug Development Summit - Bringing The European IO Community Together To Foster The Next Wave Of IO Therapeutics
- GCCL And GemPharmatech Sign MOU To Advance Global Drug Discovery And Development Services
- Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA For Previously Treated Metastatic Pancreatic Cancer
- Lonza And Engitix Announce License Agreement To Advance Targeted ADC Development
- Tract Bio Announces Presentations At Two AACR Conferences
- Acrivon To Highlight The Power Of Its AP3 Platform For Streamlined, Pathway-Based Drug Discovery And Development With Oral And Poster Presentations At AACR D3 Conference
- Phanes Therapeutics Announces Expansion Of Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate Spevatamig In Combination With KEYTRUDA® (Pembrolizumab) And Chemotherapy For Treatment Of Biliary Tract Cancer
- TriLink BioTechnologies Further Strengthens Global IP Position With Newly Issued Patent In China For CleanCap Capping Technology
ARCHIVED NEWSLETTER
- 07.28.26 -- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3)
- 07.22.26 -- Advancing Spatial Multiomics For Discovery: From Promise To Practice
- 07.21.26 -- Advancing Spatial Multiomics For Discovery: From Promise To Practice
- 07.15.26 -- Human-Centric Models For Modern Drug Development
- 07.14.26 -- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
